Is 40 mg weekly a defensible maintenance dose for tirzepatide?

Conditions: 40 mg · tirzepatide.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

How would you structure this, and what thresholds would you set in advance?

The titration schedule is a tolerability instrument, not an efficacy one. Nothing in the ladder is there to make the compound work better; every step exists to make the gastrointestinal adverse-event curve survivable.

The argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.

Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.

Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.

edited 29 Jan 2025 by Dr_Ilse_Vandenberg — fixed an arithmetic slip in the third paragraph

What the label says and what the trial protocols permitted are different documents, and the difference is instructive: protocols generally allowed a step to be delayed or reversed for intolerance, and a substantial minority of participants used that provision.

Where the label ladders differ between agents, the differences track the potency ratio and the tolerability profile rather than anything deeper. It is worth reading the ladders side by side once, because the pattern — small starting dose, four-week steps, a defined maintenance range and a defined maximum — is identical in structure across the class.

Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.

The STEP programme escalated semaglutide over sixteen weeks in four-week steps to 2.4 mg weekly, and the trial-product estimand versus treatment-policy estimand distinction accounts for most of the difference between the figures quoted from those papers.

The short version: four-week steps because that is steady state, and the ladder is about the side effects, not the result.

It helps to be literal here: for a compound with a seven-day half-life, dose timing is much less consequential than people expect and dose rate is much more consequential.

The maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.

If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.

In practice, four weeks is not a magic number, it is approximately five half-lives, which is the interval over which a weekly compound reaches steady state after a dose change. Escalating faster means escalating onto a rising concentration.

Holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

SURMOUNT-1 used a twenty-week escalation of tirzepatide in 2.5 mg increments to maintenance doses of 5, 10 and 15 mg weekly, and reported a clear dose-response across those maintenance levels — which is the closest thing to evidence that the top of the ladder does more than the middle.

Worth noting that inter-individual variability in exposure at a given dose is substantial, which is why the ladder exists rather than a single population dose.

Write down in advance what would make you hold a step, because deciding that in the middle of a bad week is not when you are at your most analytical.